We are seeking a highly motivated Project Manager to join our Clinical Operations team. This role will own the operational delivery and patient enrollment funnel for a portfolio of oncology and hematology clinical trials.
Requirements
- Own a portfolio of oncology clinical trials, ensuring deliverables and enrollment targets are met.
- Manage trial dashboards and funnels for each assigned study: monitor leads, onboarded patients, eligibility, enrollment, last-mile and medical records status, and flag risks early.
- Drive cross-functional execution with Marketing, Provider Engagement, Clinical Operations and other teams to increase qualified leads and eligible patients, accelerate medical record collection and last-mile steps, re-route or prioritize patients across trials with overlapping eligibility, and prepare and maintain weekly/bi-weekly internal updates on trial status, risks, and mitigation plans for Clinical Operations leadership.
- Support Program/Client Success Managers by providing trial performance data, insights, and slides for recurring sponsor meetings and presentations.
- Track and follow up on action items from internal and client meetings, ensuring nothing falls through the cracks.
- Ensure accurate, timely documentation of trial and patient status in internal dashboards, CRM and EMR systems.
- Contribute to continuous improvement of dashboards, SOPs and workflows for trial- and cohort-driven management.
- As needed, support preparation of client-facing materials and documentation (e.g., status summaries, decks, updates) related to trial delivery and performance.
Benefits
- Exposure to cutting-edge oncology and hematology clinical trials with leading global sponsors.
- The opportunity to directly impact patient access and trial performance across multiple cancer types and geographies.
- A fully remote, international, mission-driven environment with colleagues in Clinical Operations, Provider Engagement, Marketing, and Technology.
- Room to grow as Massive Bio scales its clinical trial portfolio and invests further in trial- and cohort-driven management.